has turned the home into the exam room of the future, making testing simpler, easier, and more reliable for patients. With Kit, patients no longer have to go into a doctor’s office or visit a lab for certain exams —they can do it all from their homes.

Phil Fung

Tech Brief

Kit differentiates in the market based on our technology, customization, and competitive pricing. We’ve built proprietary technology in specimen collection, web-based applications, and FHIR-based APIs that can connect seamlessly to electronic health records. Kit’s proprietary mini centrifuge allows for more tests processed on a sample of around 8-10 drops of blood with sample stability for 7-8 days. Current at-home tests use dried blood spot cards, which can only be designated as ‘screenings,’ while Kit uses wet-blood samples that provide the same clinical accuracy found in traditional labs. Kit’s business model is strictly B2B; therefore, we provide co-branding or white-labeling services to our partners, allowing them to empower their brands. Not only do we customize the Kit branding, instructions, and Kit components, but also can deliver customized test panels. Current at-home tests may allow a panel of 1-8 non-configurable assays, while Kit can customize a panel with up to 18 tests based on patient needs. This allows greater flexibility, cost efficiencies, and a better user experience for the end-taker since they can receive more clinical data from only a fingerprick. Kit provides highly competitive pricing, ranging from $50 to $125 per kit, including shipping, materials, labor, test panels, Kit customization, engagement, lab processing, and access to a live agent during the test process. Specific pricing is based on components chosen (e.g., blood kit, blood pressure cuff, scale, etc.), the specific lab assays run (e.g., yearly checkup blood panel, covid, lipid panel, diabetes, colon cancer screen, etc.), and volume estimates.

Problem Tech Solves

According to the American Clinical Laboratory Association, there are approximately 7 billion laboratory tests performed annually in more than 200,000 CLIA-certified laboratories in the U.S. At-home testing proliferated during the COVID-19 pandemic, with self-reported at-home testing increasing to 11% by January 2022 according to the CDC. The at-home testing industry may be worth over $2 billion by 2025. While there has been impressive growth in the at-home diagnostics industry in a short time, it still lags significantly compared to telehealth adoption. According to the 2021 Telehealth Survey Report from the American Medical Association (AMA), 85% of physician respondents indicated they used telehealth, while only 8% stated they were using remote patient monitoring technologies such as blood pressure cuffs or body weight scales. Kit fills in the diagnostics gap by providing convenience, access, and ease of use that we've received in telehealth and prescription delivery services. Without leaving their homes, healthcare consumers can initiate a full end-to-end healthcare experience with provider consultations, diagnostics, and prescription delivery. Kit facilitates a monumental shift in how consumers access labs; we believe a quarter of standard labs and biometric screenings can be conducted in the home in the next five years. This accessibility is imperative for those with chronic conditions that have challenges leaving their homes, people living in rural areas with limited transportation to nearby labs or are not covered by mobile phlebotomists, or those who strive for greater convenience in taking health action.


An independent survey from a health insurance partner showed a 9:1 preference for Kit vs. phlebotomist or clinic (n=30). Kit’s completion rate amongst the same client was 86% (n=30). The completion status breakdown was as follows: % Complete (full panel) = 86% % Complete (partial panel) = 2% % Weight, blood pressure only = 4% % Unreturned box = 8% The total completion rate is significantly higher than the industry average of 20%. Kit’s clinical accuracy for results comparing a gold standard venous blood draw vs. Kit’s results was above .95 R2 correlation coefficient for all analytes (n=63). The clinical accuracy has cultivated trust in provider networks, allowing providers and patients to save time and money. Consumers do not have additional costs related to transportation, parking, time lost, child care or caretaker care, or mobile phlebotomy visits. Providers can have more productive clinical conversations with access to test results before meeting a patient for the first time. Kit has transformed digital health with Ro, shaping the direct-to-consumer landscape by providing men's and woman's health labs.